ASCO 2022 Conference Coverage
Playback speed
10 seconds
Lecture Summary - ASCO 2022 Combi-TED: A Multicenter Phase II Trial Evaluating Efficacy of Tedopi + Docetaxel or Tedopi + Nivo as 2L Therapy in mNSCLC Progressing After 1L Chemo-Immunotherapy
By
ASCO 2022 Conference Coverage
FEATURING
Federico Cappuzzo
By
ASCO 2022 Conference Coverage
FEATURING
Federico Cappuzzo
11 views
June 10, 2022
Login to view comments.
Click here to Login
Lung